Expanding the Alzheimer Drug Development Pipeline

Commentary|Videos|September 12, 2025 Expanding the Alzheimer Drug Development Pipeline Author(s)Sharon Cohen, MD, FRCPC In this seventh episode, Cohen outlined emerging Alzheimer therapies targeting amyloid, tau, and inflammation, highlighting novel antibody approaches, genetic knockdown strategies, and repurposed GLP-1 receptor agonists. Supported by Eli Lilly. At the 2025 Alzheimer’s Association International Conference, held July 27-30, in Toronto, Canada, Alzheimer disease (AD) expert Sharon Cohen, MD, FRCPC, spoke with NeurologyLive® to discuss the use of emerging AD therapies, specifically focusing on approved antiamyloid antibodies lecanemab (Leqembi; Eisai) and donanemab (Kisulna; Eli Lilly). In this part of the video series, Cohen highlighted key differences between these AD treatments, such as eligibility requirements and safety protocols. She also highlighted amyloid related imaging abnormalities (ARIA) risks and the importance of aligning patient expectations with treatment goals.In the seventh episode of this AAIC Special Report, Cohen discussed the diverse and evolving drug development pipeline for AD. She noted the promise of next-generation antiamyloid antibodies, genetic approaches to reducing amyloid production, and oral drugs that work by preventing toxic oligomer formation. Beyond amyloid, she emphasized emerging antitau therapies as well as the potential benefit of combining amyloid and tau treatments. Cohen also pointed to inflammation as an important target, with GLP-1 receptor agonists in phase 3 trials showing potential for neuroprotection in early AD.Transcript below edited for clarity.Sharon Cohen, MD, FRCPC: The drug development pipeline for AD is quite varied. So, we have antiamyloid drugs. We've talked about a couple of them that have regulatory approval now in many countries, but there are others under development that are antibodies that show very rapid clearance of amyloid with almost no ARIA. So, that's very exciting. That's the trontinemab phase 2 data—the ability to get an antibody into the brain using a brain shuttle approach. We'll see what phase 3 brings, but I think there's a lot of enthusiasm about that.There are other approaches that are earlier in development, but they are genetically engineered to shut off production of amyloid. That would be the Alnylam Pharmaceuticals mivelsiran program, where intrathecal dosing every 6 months may really knock down the production of all daughter proteins of amyloid precursor proteins. So, that's exciting.In between, we have valiltramiprosate, which is also working on the amyloid therapeutic target area, but it works differently. It's an oral drug, and particularly in APOE4 homozygotes who maybe don't have other treatment options with the same safety as nonAPOE4 homozygotes, we have a drug that stops monomers of amyloid from becoming oligomers. Oligomers are felt to be the most toxic. So, I've talked a lot about the antiamyloid approaches. It's not all antibodies, and we'll see what the field brings.However, tau is also a bad actor in AD, and we have a new generation of antitau antibodies that are targeting the mid-domain of tau in the hope that we can shut off cell-to-cell spread of tau. There are several of these in phase 2. There's also an antisense oligonucleotide, again getting at the genetic knockdown approach. This is a Biogen BIIB080 drug that shuts off production of tau. So, that will be very interesting.I think the combination of treating amyloid and tau—whether it's sequentially or immediately in a symptomatic patient, because both amyloid and tau are already acting in the brain in patients who have Alzheimer symptoms—will be important.Then you have other approaches. Maybe I'll just mention briefly, because I could go on and on here—you can see I'm excited about it—but the role of inflammation is important in AD. It's also a bad actor, and maybe not just at the endpoint of disease, but even early on. So, there are a number of drugs acting differently in the drug development pipeline to target inflammation. But one of them that will be familiar to many clinicians is this class of drug, GLP-1 receptor agonists. Specifically, semaglutide, under development by Novo Nordisk, will read out its phase 3 program in AD—in early Alzheimer, MCI, and mild dementia because of Alzheimer—to see if we get a neuroprotective effect. We will have that data by the end of this year. I think it will be reported at CTAD.So, very exciting to think that we'll have an oral drug that is repurposed from diabetes and obesity. This class of drugs is now expanding in its indications, but originally it was a diabetes drug, familiar to many practitioners who aren't Alzheimer specialists, and maybe an option for individuals with early AD. NewsletterKeep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.Subscribe Now! Related ArticlesNeurologyLive® Friday 5 — September 12, 2025September 12th 2025Shared Decision-Making and Ethics in Complex Neurology Clinical Research: Paul Ford, PhDSeptember 12th 2025FDA Hands Complete Response Letter to SL1009 for Pyruvate Dehydrogenase Complex DeficiencySeptember 12th 2025Special Episode: Understanding Fremanezumab's Expanded Indication in Pediatric MigraineSeptember 12th 2025Enhancing Gene Therapy Safety for Duchenne Through New Recommendations: Barry Byrne, MD, PhDSeptember 11th 2025Shifting Roles in Neurology Education: Insights From the 2025 AUPN Annual MeetingSeptember 11th 2025 Latest CMEMultimediaBurst CME™ Part II: The Evolving Treatment Landscape for Huntington DiseaseSamuel A. Frank, MDView moreIn-Person + Virtual EventCarolina Neuromuscular Disease SummitSeptember 27, 2025View moreVideoEvolving Perspectives in Alzheimer's Disease: Reaching an Earlier Diagnosis, Understanding Neuroinflammation, and Exploring Therapeutic AdvancesAlireza Atri, MD, PhD; Erik S. Musiek, MD, PhD; Malú Gámez Tansey, PhD View moreCase-based SimulationSimulatEd™ From Discomfort to Relief: Acute Pain Management EssentialsJeff Gudin, MDView moreMultimedia Clinical ShowCase: Developing a Personalized Treatment Plan for a Patient with Huntington’s Disease Associated ChoreaDaniel Claassen, MD, MS; Martha A. Nance, MDView moreIn-Person + Virtual EventPutting the Patient First in Acute Pain Management: The PA’s Guide to Incorporating Cutting-Edge Science into their Treatment StrategiesOctober 9, 2025View moreIn-Person Event4th Women in Neurology ConferenceOctober 24-26, 2025Register now!VideoMedical Crossfire® - Optimizing Management for Patients With Generalized Myasthenia Gravis: Focus on Complement InhibitorsJames F. Howard Jr, MD; Nicholas J. Silvestri, MD, FAAN; Neelam Goyal, MDView moreVideoMedical Crossfire®: Integrating Real-World Data to Improve Outcomes for Patients With Multiple SclerosisCarrie M. Hersh, DO, MSc, FAAN; Anna Shah, MDView moreMultimediaBurst CME™: Optimizing Migraine Management – Addressing Unmet Needs, Individualizing Care for Diverse Populations, and Utilizing CGRP Targeted AgentsJessica Ailani, MD, FAHS, FAAN; Paul G. Mathew, MD, DNBPAS, FAAN, FAHSView moreMultimediaBurst CME™: Setting the Stage – Individualizing Migraine Care for Diverse Populations Across Care SettingsJessica Ailani, MD, FAHS, FAAN; Paul G. Mathew, MD, DNBPAS, FAAN, FAHSView moreMultimediaCommunity Practice Connections™: Optimizing the Management of Tardive Dyskinesia—Addressing the Complexity of Care With Targeted TreatmentIlan Melnick, MD; Alejandro Alva, MD; Linda Trinh, DNP, PMHNP, FNP, MPHView moreMultimediaBurst CME™: Optimizing the Use of CGRP Targeted Agents for the Treatment of MigraineJessica Ailani, MD, FAHS, FAAN; Paul G. Mathew, MD, DNBPAS, FAAN, FAHSView moreMultimediaBurst CME™: The Patient Journey – Unmet Needs From Diagnosis Through Management of MigraineJessica Ailani, MD, FAHS, FAAN; Paul G. Mathew, MD, DNBPAS, FAAN, FAHSView moreMultimedia Evolving Perspectives in Alzheimer Disease : Reaching an Earlier Diagnosis, Understanding Neuroinflammation, and Exploring Therapeutic AdvancesAlireza Atri, MD, PhD; Erik S. Musiek, MD, PhD; Malú Gámez Tansey, PhDView moreVirtual EventExpert Illustrations & Commentaries™: Visualizing the Role of B Cells as Therapeutic Targets for Generalized Myasthenia GravisOctober 31, 2025View moreVideoCases and Conversations™: Applying Best Practices to Prevent Shingles in Your PracticePaul G. Auwaerter, MD, MBA; Paul P. Doghramji, MD, FAAFP; Aruna Subramanian, MDView moreVideoPatient, Provider, and Caregiver Connection™: Pediatric Myasthenia Gravis—Current Treatment and Emerging ConceptsJohn F. Brandsema, MD; Abigail N. Schwaede, MD; Samuel J. Mackenzie, MD, PhDView moreAudioMind Moments™: Optimizing Management for Patients with Generalized Myasthenia GravisJames F. Howard Jr, MDView moreVideoIdentifying and Treating CIDP in the Modern EraJeffrey A. Allen, MD; Karissa L. Gable, MDView moreVideoCases and Conversations™: Little Voices, Big Challenges – Comprehensive Care for Pediatric Spinal Muscular AtrophyJohn Brandsema, MD; Carla D. Zingariello, DOView moreVideoCases and Conversations™: Navigating the Complexities of Managing Myasthenia Gravis in Pediatric and Pregnant Patient PopulationsJohn Brandsema, MD; Neelam Goyal, MDView moreVideoA Breath of Strength: Managing Cancer Associated LEMS and Lung Cancer as OneEstelamari Rodriguez, MD, MPH; Millie Das, MD; Ruham Nasany, MDView moreVideoStriking the Right Nerve: Managing Cancer Associated LEMS in Lung Cancer PatientsAnne Chiang, MD, PhD; J. Douglas Miles, MD, PhD, FAAN; Suma Satti, MDView moreVideoPatient, Provider, and Caregiver Connection: Improving Diagnosis and Care for Adolescent Myasthenia Gravis Patients – A New FrontierAbigail N. Schwaede, MD; Emmanuelle (Noelle) Tiongson, MDView moreVideoA New Era in NMOSD Treatment: Optimizing Therapeutic Transitions and Reducing Patient BurdenShamik Bhattacharyya, MD, MS, FAAN; Mirla Avila, MD; Dean Wingerchuk, MDView moreAudioPER Podcast™: Maximizing the Multidisciplinary Care Outcomes of Patients with Amyotrophic Lateral Sclerosis (ALS)Richard Bedlack, MD, PhDView moreAudioPER Podcast™: Best Strategies for Approaching the Diagnosis of Amyotrophic Lateral Sclerosis (ALS)Terry Heiman-Patterson, MDView moreVideoPER Postgame™: Updates from ANNA in the Management of IgA NephropathyGerald Bernard Appel, MD; Ellie Kelepouris, MD, FACP, FAHAView moreVideoPatient, Provider, and Caregiver Connection: Turning a New Leaf in Acute Pain Management – How Recent Advancements Impact the Treatment ParadigmJeffrey Gudin, MD; Jeffrey Bettinger, PharmDView morePrevious slideNext slide Trending on NeurologyLive1Enhancing Gene Therapy Safety for Duchenne Through New Recommendations: Barry Byrne, MD, PhD2Expanding the Alzheimer Drug Development Pipeline 3FDA Hands Complete Response Letter to SL1009 for Pyruvate Dehydrogenase Complex Deficiency4Patient-Reported Study Identifies Common Symptoms and Timing During Migraine Prodrome 5Setting Realistic Expectations for Antiamyloid Therapeutics Commentary|Videos|September 12, 2025 Expanding the Alzheimer Drug Development Pipeline Author(s)Sharon Cohen, MD, FRCPC In this seventh episode, Cohen outlined emerging Alzheimer therapies targeting amyloid, tau, and inflammation, highlighting novel antibody approaches, genetic knockdown strategies, and repurposed GLP-1 receptor agonists. Supported by Eli Lilly. At the 2025 Alzheimer’s Association International Conference, held July 27-30, in Toronto, Canada, Alzheimer disease (AD) expert Sharon Cohen, MD, FRCPC, spoke with NeurologyLive® to discuss the use of emerging AD therapies, specifically focusing on approved antiamyloid antibodies lecanemab (Leqembi; Eisai) and donanemab (Kisulna; Eli Lilly). In this part of the video series, Cohen highlighted key differences between these AD treatments, such as eligibility requirements and safety protocols. She also highlighted amyloid related imaging abnormalities (ARIA) risks and the importance of aligning patient expectations with treatment goals.In the seventh episode of this AAIC Special Report, Cohen discussed the diverse and evolving drug development pipeline for AD. She noted the promise of next-generation antiamyloid antibodies, genetic approaches to reducing amyloid production, and oral drugs that work by preventing toxic oligomer formation. Beyond amyloid, she emphasized emerging antitau therapies as well as the potential benefit of combining amyloid and tau treatments. Cohen also pointed to inflammation as an important target, with GLP-1 receptor agonists in phase 3 trials showing potential for neuroprotection in early AD.Transcript below edited for clarity.Sharon Cohen, MD, FRCPC: The drug development pipeline for AD is quite varied. So, we have antiamyloid drugs. We've talked about a couple of them that have regulatory approval now in many countries, but there are others under development that are antibodies that show very rapid clearance of amyloid with almost no ARIA. So, that's very exciting. That's the trontinemab phase 2 data—the ability to get an antibody into the brain using a brain shuttle approach. We'll see what phase 3 brings, but I think there's a lot of enthusiasm about that.There are other approaches that are earlier in development, but they are genetically engineered to shut off production of amyloid. That would be the Alnylam Pharmaceuticals mivelsiran program, where intrathecal dosing every 6 months may really knock down the production of all daughter proteins of amyloid precursor proteins. So, that's exciting.In between, we have valiltramiprosate, which is also working on the amyloid therapeutic target area, but it works differently. It's an oral drug, and particularly in APOE4 homozygotes who maybe don't have other treatment options with the same safety as nonAPOE4 homozygotes, we have a drug that stops monomers of amyloid from becoming oligomers. Oligomers are felt to be the most toxic. So, I've talked a lot about the antiamyloid approaches. It's not all antibodies, and we'll see what the field brings.However, tau is also a bad actor in AD, and we have a new generation of antitau antibodies that are targeting the mid-domain of tau in the hope that we can shut off cell-to-cell spread of tau. There are several of these in phase 2. There's also an antisense oligonucleotide, again getting at the genetic knockdown approach. This is a Biogen BIIB080 drug that shuts off production of tau. So, that will be very interesting.I think the combination of treating amyloid and tau—whether it's sequentially or immediately in a symptomatic patient, because both amyloid and tau are already acting in the brain in patients who have Alzheimer symptoms—will be important.Then you have other approaches. Maybe I'll just mention briefly, because I could go on and on here—you can see I'm excited about it—but the role of inflammation is important in AD. It's also a bad actor, and maybe not just at the endpoint of disease, but even early on. So, there are a number of drugs acting differently in the drug development pipeline to target inflammation. But one of them that will be familiar to many clinicians is this class of drug, GLP-1 receptor agonists. Specifically, semaglutide, under development by Novo Nordisk, will read out its phase 3 program in AD—in early Alzheimer, MCI, and mild dementia because of Alzheimer—to see if we get a neuroprotective effect. We will have that data by the end of this year. I think it will be reported at CTAD.So, very exciting to think that we'll have an oral drug that is repurposed from diabetes and obesity. This class of drugs is now expanding in its indications, but originally it was a diabetes drug, familiar to many practitioners who aren't Alzheimer specialists, and maybe an option for individuals with early AD. NewsletterKeep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.Subscribe Now! Related ArticlesNeurologyLive® Friday 5 — September 12, 2025September 12th 2025Shared Decision-Making and Ethics in Complex Neurology Clinical Research: Paul Ford, PhDSeptember 12th 2025FDA Hands Complete Response Letter to SL1009 for Pyruvate Dehydrogenase Complex DeficiencySeptember 12th 2025Special Episode: Understanding Fremanezumab's Expanded Indication in Pediatric MigraineSeptember 12th 2025Enhancing Gene Therapy Safety for Duchenne Through New Recommendations: Barry Byrne, MD, PhDSeptember 11th 2025Shifting Roles in Neurology Education: Insights From the 2025 AUPN Annual MeetingSeptember 11th 2025 Latest CMEMultimediaBurst CME™ Part II: The Evolving Treatment Landscape for Huntington DiseaseSamuel A. Frank, MDView moreIn-Person + Virtual EventCarolina Neuromuscular Disease SummitSeptember 27, 2025View moreVideoEvolving Perspectives in Alzheimer's Disease: Reaching an Earlier Diagnosis, Understanding Neuroinflammation, and Exploring Therapeutic AdvancesAlireza Atri, MD, PhD; Erik S. Musiek, MD, PhD; Malú Gámez Tansey, PhD View moreCase-based SimulationSimulatEd™ From Discomfort to Relief: Acute Pain Management EssentialsJeff Gudin, MDView moreMultimedia Clinical ShowCase: Developing a Personalized Treatment Plan for a Patient with Huntington’s Disease Associated ChoreaDaniel Claassen, MD, MS; Martha A. Nance, MDView moreIn-Person + Virtual EventPutting the Patient First in Acute Pain Management: The PA’s Guide to Incorporating Cutting-Edge Science into their Treatment StrategiesOctober 9, 2025View moreIn-Person Event4th Women in Neurology ConferenceOctober 24-26, 2025Register now!VideoMedical Crossfire® - Optimizing Management for Patients With Generalized Myasthenia Gravis: Focus on Complement InhibitorsJames F. Howard Jr, MD; Nicholas J. Silvestri, MD, FAAN; Neelam Goyal, MDView moreVideoMedical Crossfire®: Integrating Real-World Data to Improve Outcomes for Patients With Multiple SclerosisCarrie M. Hersh, DO, MSc, FAAN; Anna Shah, MDView moreMultimediaBurst CME™: Optimizing Migraine Management – Addressing Unmet Needs, Individualizing Care for Diverse Populations, and Utilizing CGRP Targeted AgentsJessica Ailani, MD, FAHS, FAAN; Paul G. Mathew, MD, DNBPAS, FAAN, FAHSView moreMultimediaBurst CME™: Setting the Stage – Individualizing Migraine Care for Diverse Populations Across Care SettingsJessica Ailani, MD, FAHS, FAAN; Paul G. Mathew, MD, DNBPAS, FAAN, FAHSView moreMultimediaCommunity Practice Connections™: Optimizing the Management of Tardive Dyskinesia—Addressing the Complexity of Care With Targeted TreatmentIlan Melnick, MD; Alejandro Alva, MD; Linda Trinh, DNP, PMHNP, FNP, MPHView moreMultimediaBurst CME™: Optimizing the Use of CGRP Targeted Agents for the Treatment of MigraineJessica Ailani, MD, FAHS, FAAN; Paul G. Mathew, MD, DNBPAS, FAAN, FAHSView moreMultimediaBurst CME™: The Patient Journey – Unmet Needs From Diagnosis Through Management of MigraineJessica Ailani, MD, FAHS, FAAN; Paul G. Mathew, MD, DNBPAS, FAAN, FAHSView moreMultimedia Evolving Perspectives in Alzheimer Disease : Reaching an Earlier Diagnosis, Understanding Neuroinflammation, and Exploring Therapeutic AdvancesAlireza Atri, MD, PhD; Erik S. Musiek, MD, PhD; Malú Gámez Tansey, PhDView moreVirtual EventExpert Illustrations & Commentaries™: Visualizing the Role of B Cells as Therapeutic Targets for Generalized Myasthenia GravisOctober 31, 2025View moreVideoCases and Conversations™: Applying Best Practices to Prevent Shingles in Your PracticePaul G. Auwaerter, MD, MBA; Paul P. Doghramji, MD, FAAFP; Aruna Subramanian, MDView moreVideoPatient, Provider, and Caregiver Connection™: Pediatric Myasthenia Gravis—Current Treatment and Emerging ConceptsJohn F. Brandsema, MD; Abigail N. Schwaede, MD; Samuel J. Mackenzie, MD, PhDView moreAudioMind Moments™: Optimizing Management for Patients with Generalized Myasthenia GravisJames F. Howard Jr, MDView moreVideoIdentifying and Treating CIDP in the Modern EraJeffrey A. Allen, MD; Karissa L. Gable, MDView moreVideoCases and Conversations™: Little Voices, Big Challenges – Comprehensive Care for Pediatric Spinal Muscular AtrophyJohn Brandsema, MD; Carla D. Zingariello, DOView moreVideoCases and Conversations™: Navigating the Complexities of Managing Myasthenia Gravis in Pediatric and Pregnant Patient PopulationsJohn Brandsema, MD; Neelam Goyal, MDView moreVideoA Breath of Strength: Managing Cancer Associated LEMS and Lung Cancer as OneEstelamari Rodriguez, MD, MPH; Millie Das, MD; Ruham Nasany, MDView moreVideoStriking the Right Nerve: Managing Cancer Associated LEMS in Lung Cancer PatientsAnne Chiang, MD, PhD; J. Douglas Miles, MD, PhD, FAAN; Suma Satti, MDView moreVideoPatient, Provider, and Caregiver Connection: Improving Diagnosis and Care for Adolescent Myasthenia Gravis Patients – A New FrontierAbigail N. Schwaede, MD; Emmanuelle (Noelle) Tiongson, MDView moreVideoA New Era in NMOSD Treatment: Optimizing Therapeutic Transitions and Reducing Patient BurdenShamik Bhattacharyya, MD, MS, FAAN; Mirla Avila, MD; Dean Wingerchuk, MDView moreAudioPER Podcast™: Maximizing the Multidisciplinary Care Outcomes of Patients with Amyotrophic Lateral Sclerosis (ALS)Richard Bedlack, MD, PhDView moreAudioPER Podcast™: Best Strategies for Approaching the Diagnosis of Amyotrophic Lateral Sclerosis (ALS)Terry Heiman-Patterson, MDView moreVideoPER Postgame™: Updates from ANNA in the Management of IgA NephropathyGerald Bernard Appel, MD; Ellie Kelepouris, MD, FACP, FAHAView moreVideoPatient, Provider, and Caregiver Connection: Turning a New Leaf in Acute Pain Management – How Recent Advancements Impact the Treatment ParadigmJeffrey Gudin, MD; Jeffrey Bettinger, PharmDView morePrevious slideNext slide Trending on NeurologyLive1Enhancing Gene Therapy Safety for Duchenne Through New Recommendations: Barry Byrne, MD, PhD2Expanding the Alzheimer Drug Development Pipeline 3FDA Hands Complete Response Letter to SL1009 for Pyruvate Dehydrogenase Complex Deficiency4Patient-Reported Study Identifies Common Symptoms and Timing During Migraine Prodrome 5Setting Realistic Expectations for Antiamyloid Therapeutics